These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 32701559)

  • 1. Aldophosphamide-thiazolidine (NSC-613060) an oxazaphosphorine cytostatic that crosses the blood brain barrier.
    Voelcker G
    Anticancer Drugs; 2021 Jan; 32(1):61-65. PubMed ID: 32701559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
    Voelcker G; Bielicki L; Hohorst HJ
    J Cancer Res Clin Oncol; 1997; 123(11-12):623-31. PubMed ID: 9620221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
    Friedman OM; Wodinsky I; Myles A
    Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity.
    Voelcker G
    Anticancer Drugs; 2018 Jan; 29(1):75-79. PubMed ID: 29219879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotoxic, cytostatic, antineoplastic and apoptotic effects of newly synthesized antitumour steroidal esters.
    Karapidaki I; Bakopoulou A; Papageorgiou A; Iakovidou Z; Mioglou E; Nikolaropoulos S; Mourelatos D; Lialiaris T
    Mutat Res; 2009 Apr; 675(1-2):51-9. PubMed ID: 19386248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Causes and possibilities to circumvent cyclophosphamide toxicity.
    Voelcker G
    Anticancer Drugs; 2020 Jul; 31(6):617-622. PubMed ID: 32044797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism and transport of oxazaphosphorines and the clinical implications.
    Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
    Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies.
    Sonawat HM; Leibfritz D; Engel J; Hilgard P
    Biochim Biophys Acta; 1990 Apr; 1052(1):36-41. PubMed ID: 2322593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine.
    Voelcker G; Pfeiffer B; Schnee A; Hohorst H
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):74-8. PubMed ID: 10664245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostimulating and cancer-reductive experimental therapy with the oxazaphosphorine cytostatic SUM-IAP.
    Voelcker G
    Anticancer Drugs; 2018 Jun; 29(5):411-415. PubMed ID: 29465464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes.
    Cox PJ; Phillips BJ; Thomas P
    Cancer Treat Rep; 1976 Apr; 60(4):321-6. PubMed ID: 179712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytostatic activity of an estradiol-linked nitrosourea in MXT mammary carcinoma and L 5222 leukemia.
    Zeller WJ; Schreiber J; Petru E; Eisenbrand G
    Arzneimittelforschung; 1989 Dec; 39(12):1577-9. PubMed ID: 2624608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of new oxazaphosphorine anticancer drugs.
    Liang J; Huang M; Duan W; Yu XQ; Zhou S
    Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldophosphamide: synthesis, characterization, and comparison with "Hohorst's aldophosphamide".
    Struck RF
    Cancer Treat Rep; 1976 Apr; 60(4):317-9. PubMed ID: 1277207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.
    Fenselau C; Kan MN; Rao SS; Myles A; Friedman OM; Colvin M
    Cancer Res; 1977 Aug; 37(8 Pt 1):2538-43. PubMed ID: 872080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Half-life of oxazaphosphorines in biological fluids.
    Sladek NE; Powers JF; Grage GM
    Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the pretreatment with some cytostatic agents on the growth rate of leukaemia L5178Y.
    Bohunickå E; Koza I; Ujhåzy V
    Neoplasma; 1974; 21(6):659-63. PubMed ID: 4479976
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
    Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z
    J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies on NSC290205 aza-steroid alkylator activity in combination with adriamycin against lymphoid leukaemia.
    Trafalis DT; Tsavdaridis D; Camoutsis C; Karayiani V; Mourelatos D; Dalezis P; Athanassiou A; Pangalis GA; Papageorgiou A
    Br J Haematol; 2005 Feb; 128(3):343-50. PubMed ID: 15667536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships in antitumor aniline mustards.
    Panthananickal A; Hansch C; Leo A
    J Med Chem; 1978 Jan; 21(1):16-26. PubMed ID: 619146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.